Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells which remains incurable, despite significant improvements in treatment and patient care. There is an urgent need to identify novel markers with prognostic and therapeutic value for MM. Long non-coding RNAs (lncRNAs) have emerged as key regulators in cancers including MM. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a lncRNA known to be over expressed in solid tumors and hematologic malignancies. However, the pathological mechanisms of MALAT1 in MM are not completely understood. Objective: To investigate the MALAT1 expression levels in MM patients and to evaluate their relations to disease characteristics and possible prognostic implication. Patients and methods: The study was performed on 50 MM patients and 50 patients doing bone marrow aspiration for other conditions with normal plasma cell percentage as controls. Total RNA, including LncRNA isolation from bone marrow samples was carried out with the miRN easy Mini Kit according to the manufacturer’s instructions. MALAT1 gene expression was performed by RNA extraction, reverse transcription, and real-time qPCR. Results: We demonstrated that MALAT1 was over expressed in newly diagnosed MM patients compared with post-treatment patients and control subjects. Additionally, there were statistically significant relations between high MALAT1 expression levels and ESR, plasma cell percentages in bone marrow, M-protein concentrations in serum protein electrophoresis (SPEP), hemoglobin levels and serum levels of β2-microglobulin and IL-6. Conclusion: The current data suggested that MALAT1 may be useful as a novel prognostic biomarker for MM.
多发性骨髓瘤(MM)是一种抗体分泌浆细胞的恶性肿瘤，尽管在治疗和患者护理方面取得了重大进展，但仍然无法治愈。长链非编码rna (lncRNAs)已成为包括MM在内的癌症的关键调节因子。转移相关肺腺癌转录物1 (MALAT1)是一种已知在实体瘤和血液系统恶性肿瘤中过表达的lncRNA。然而，MALAT1在MM中的病理机制尚不完全清楚。目的:探讨MM患者MALAT1的表达水平，探讨其与疾病特征的关系及可能的预后意义。患者和方法:50例MM患者和50例其他情况骨髓抽吸患者，浆细胞百分比正常为对照。根据制造商的说明，使用miRN easy Mini Kit从骨髓样本中分离总RNA，包括LncRNA。通过RNA提取、反转录和实时qPCR进行MALAT1基因表达。结果:与治疗后患者和对照组相比，我们发现MALAT1在新诊断的MM患者中过表达。此外，高MALAT1表达水平与ESR、骨髓浆细胞百分比、血清蛋白电泳(SPEP) m蛋白浓度、血红蛋白水平、血清β2-微球蛋白和IL-6水平有统计学意义。结论:目前的数据表明MALAT1可能是一种新的MM预后生物标志物。
{"title":"Metastasis-Associated Lung Adenocarcinoma Transcript 1 Expression Levels in Egyptian Patients with Multiple Myeloma: Relation to Disease Characteristics and Possible Prognostic Implication","authors":"I. Shaaban, Maha Gammal","doi":"10.18689/MJCSR-1000114","DOIUrl":"https://doi.org/10.18689/MJCSR-1000114","url":null,"abstract":"Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells which remains incurable, despite significant improvements in treatment and patient care. There is an urgent need to identify novel markers with prognostic and therapeutic value for MM. Long non-coding RNAs (lncRNAs) have emerged as key regulators in cancers including MM. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a lncRNA known to be over expressed in solid tumors and hematologic malignancies. However, the pathological mechanisms of MALAT1 in MM are not completely understood. Objective: To investigate the MALAT1 expression levels in MM patients and to evaluate their relations to disease characteristics and possible prognostic implication. Patients and methods: The study was performed on 50 MM patients and 50 patients doing bone marrow aspiration for other conditions with normal plasma cell percentage as controls. Total RNA, including LncRNA isolation from bone marrow samples was carried out with the miRN easy Mini Kit according to the manufacturer’s instructions. MALAT1 gene expression was performed by RNA extraction, reverse transcription, and real-time qPCR. Results: We demonstrated that MALAT1 was over expressed in newly diagnosed MM patients compared with post-treatment patients and control subjects. Additionally, there were statistically significant relations between high MALAT1 expression levels and ESR, plasma cell percentages in bone marrow, M-protein concentrations in serum protein electrophoresis (SPEP), hemoglobin levels and serum levels of β2-microglobulin and IL-6. Conclusion: The current data suggested that MALAT1 may be useful as a novel prognostic biomarker for MM.","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48014508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A historical reconstruction of the holistic approach to cancer is presented. A particular attention is given to the United States, since, after reductionism had prevailed in Western world, New York Jungian psychoanalyst Elida Evans published the first modern monograph about the psychology of cancer patients in 1926, proposing a holistic view of cancer again. Evans’ theory has largely influenced cancer psychosomatics. Without pretension of completeness, research on cancer is discussed in its epidemiological, social, environmental, behavioural, and psychoanalytical aspects. The results of psychoneuroimmunology and the discoveries of developmental psychobiology are highlighted for their importance in a holistic vision of cancer. Assumption of this paper is that persistent dualism - studying body or mind - is depriving research of fundamental variables involved in human cancer; therefore, integrated multidisciplinary investigation is advocated.
{"title":"Historical-Clinical Pathways to a Cancer Holistic Perspective","authors":"Marco Balenci","doi":"10.18689/MJCSR-1000113","DOIUrl":"https://doi.org/10.18689/MJCSR-1000113","url":null,"abstract":"A historical reconstruction of the holistic approach to cancer is presented. A particular attention is given to the United States, since, after reductionism had prevailed in Western world, New York Jungian psychoanalyst Elida Evans published the first modern monograph about the psychology of cancer patients in 1926, proposing a holistic view of cancer again. Evans’ theory has largely influenced cancer psychosomatics. Without pretension of completeness, research on cancer is discussed in its epidemiological, social, environmental, behavioural, and psychoanalytical aspects. The results of psychoneuroimmunology and the discoveries of developmental psychobiology are highlighted for their importance in a holistic vision of cancer. Assumption of this paper is that persistent dualism - studying body or mind - is depriving research of fundamental variables involved in human cancer; therefore, integrated multidisciplinary investigation is advocated.","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46272540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recent findings from studies [KEYNOTE 10, 24, 189, 407 (pembrolizumab); Check Mate-17,57,227 (nivolumab); IM power 131,150,OAK (atezolizumab)] using checkpoint inhibitors as a monotherapy as well as in combination of chemotherapy has demonstrated improved outcome in patients with advanced NSCLC without actionable mutation driver and also showed a tolerable toxicity profile and durable response. Based on analysis of studies performed in the first line management of advanced NSCLC, pembrolizumab is preferred for patients without actionable driver mutation. Pembrolizumab should be used as a monotherapy in patients with PD-L1 expression ≥ 50%. In others, it should be added to chemotherapy. For patients with actionable driver mutation, osimertinib for sensitizing EGFR mutation is preferred over afatinib, gefitinib, erlotinib as a first line therapy. For patients with ALK rearrangement alectinib is preferred over crizotinib restricting use of crizotinib as first line therapy to patients with ROS1 rearrangement. Dabrafenib + trametinib have been found effective in patients with BRAFV600E mutations.
{"title":"Advances in the Management of Non-Small Cell Lung Cancer (NSCLC)","authors":"B. Khamar","doi":"10.18689/mjcsr-1000112","DOIUrl":"https://doi.org/10.18689/mjcsr-1000112","url":null,"abstract":"Recent findings from studies [KEYNOTE 10, 24, 189, 407 (pembrolizumab); Check Mate-17,57,227 (nivolumab); IM power 131,150,OAK (atezolizumab)] using checkpoint inhibitors as a monotherapy as well as in combination of chemotherapy has demonstrated improved outcome in patients with advanced NSCLC without actionable mutation driver and also showed a tolerable toxicity profile and durable response. Based on analysis of studies performed in the first line management of advanced NSCLC, pembrolizumab is preferred for patients without actionable driver mutation. Pembrolizumab should be used as a monotherapy in patients with PD-L1 expression ≥ 50%. In others, it should be added to chemotherapy. For patients with actionable driver mutation, osimertinib for sensitizing EGFR mutation is preferred over afatinib, gefitinib, erlotinib as a first line therapy. For patients with ALK rearrangement alectinib is preferred over crizotinib restricting use of crizotinib as first line therapy to patients with ROS1 rearrangement. Dabrafenib + trametinib have been found effective in patients with BRAFV600E mutations.","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44792319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Basavarajappa, R. Kamath, B. Shetty, Sreemathi S. Mayya
Results: The sex distribution male to female was 0.84:1. Majority of male (43.1%) and female (41.7%) cancer patients were from Udupi district in Karnataka. The diagnosis of cancer was confirmed by microscopic method, among men 88.2% and among women 92% cancer diagnosis was done microscopic method. In women breast was the leading site of cancer (29.6%) followed by cervix uteri (20.4%) Among men lung is the leading site of cancer (10.5%).
{"title":"Patterns of Cancer at a Tertiary Care Hospital in Karnataka-India","authors":"D. Basavarajappa, R. Kamath, B. Shetty, Sreemathi S. Mayya","doi":"10.18689/mjcsr-1000110","DOIUrl":"https://doi.org/10.18689/mjcsr-1000110","url":null,"abstract":"Results: The sex distribution male to female was 0.84:1. Majority of male (43.1%) and female (41.7%) cancer patients were from Udupi district in Karnataka. The diagnosis of cancer was confirmed by microscopic method, among men 88.2% and among women 92% cancer diagnosis was done microscopic method. In women breast was the leading site of cancer (29.6%) followed by cervix uteri (20.4%) Among men lung is the leading site of cancer (10.5%).","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45521100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-07DOI: 10.32474/CTBM.2018.01.000104
R. Skopec
There are reports about the existence of meningeal lymphatic vessels in human and nonhuman primates (mormoset monkeys) and feasibility of noninvasively imaging and mapping them in vivo with high-resolution, clinical MRI. On T2-FLAIR and T1-weighted black-blood imaging, lymphatic vessels enhance with graduator, a gadolinium-based contrast agent with high propensity to extravasate across a permeable capillary endothelial barrier, but not with gadofosveset, a blood-pool contrast agent.
{"title":"Lymph Node Blood Vessels: Exit Route for Systemic Dissemination of Cancer","authors":"R. Skopec","doi":"10.32474/CTBM.2018.01.000104","DOIUrl":"https://doi.org/10.32474/CTBM.2018.01.000104","url":null,"abstract":"There are reports about the existence of meningeal lymphatic vessels in human and nonhuman primates (mormoset monkeys)\u0000and feasibility of noninvasively imaging and mapping them in vivo with high-resolution, clinical MRI. On T2-FLAIR and T1-weighted\u0000black-blood imaging, lymphatic vessels enhance with graduator, a gadolinium-based contrast agent with high propensity to\u0000extravasate across a permeable capillary endothelial barrier, but not with gadofosveset, a blood-pool contrast agent.","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46292334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Salamoon, L. Assad, F. Ahmad, M. Kenj, M. Bachour
Results and Discussion: 2013 patients were found to be Her-2 positive (+++) forming 19.4% of the studied group, 2000 (19.3%) were (++) equivocal. On the other hand, 62% of patients were Her-2 negative (0 and 1+) scores. A further investigation of the positive and equivocal groups was performed by FISH showing positive results as follows: 1815/2013 of the (3+ patients) and 1143/2000 of the (2+ patients) respectively. In other word 57% of the (++) group were found to be FISH positive versus 9% negative FISH results in the (+++) group.
{"title":"Her-2/neu Status in Syrian Women with Breast Carcinoma: A Syrian Cohort Study of more than 10000 Cases","authors":"M. Salamoon, L. Assad, F. Ahmad, M. Kenj, M. Bachour","doi":"10.18689/mjcsr-1000109","DOIUrl":"https://doi.org/10.18689/mjcsr-1000109","url":null,"abstract":"Results and Discussion: 2013 patients were found to be Her-2 positive (+++) forming 19.4% of the studied group, 2000 (19.3%) were (++) equivocal. On the other hand, 62% of patients were Her-2 negative (0 and 1+) scores. A further investigation of the positive and equivocal groups was performed by FISH showing positive results as follows: 1815/2013 of the (3+ patients) and 1143/2000 of the (2+ patients) respectively. In other word 57% of the (++) group were found to be FISH positive versus 9% negative FISH results in the (+++) group.","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42043078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reham El Shimy Salwa Hassan Teama, H. Gamal, Salwa Teama
Results: The results showed that increased serum protein concentration of HE-4 (pMol/L) and CA-125 (U/ml) in the ovarian cancer group mean (SD)/median (range) 329.61±336.55/199 (28.72-1064) and 521.36±572.60/287 (10.50-2377), than non-cancer control group 64.80±38.51/54.53 (21 -160) and 28.35±10.80/28 (10-50) respectively (p<0.05). The receiver operating characteristic curve, the area under the curve (ROC-AUC) (95%CI) values of serum HE-4 was 0.85 (0.74-0.95). The sensitivity and specificity of HE-4 in diagnosing malignant ovarian tumors was 84.84% and 75.00%, respectively at ideal cutoff point that provided the best and highest accuracy in our own study and its level was related to clinical staging.
{"title":"Combined Human Epididymis 4 and Carbohydrate Antigen 125 Serum Protein Levels Diagnostic value in Ovarian Cancer","authors":"Reham El Shimy Salwa Hassan Teama, H. Gamal, Salwa Teama","doi":"10.18689/mjcsr-1000108","DOIUrl":"https://doi.org/10.18689/mjcsr-1000108","url":null,"abstract":"Results: The results showed that increased serum protein concentration of HE-4 (pMol/L) and CA-125 (U/ml) in the ovarian cancer group mean (SD)/median (range) 329.61±336.55/199 (28.72-1064) and 521.36±572.60/287 (10.50-2377), than non-cancer control group 64.80±38.51/54.53 (21 -160) and 28.35±10.80/28 (10-50) respectively (p<0.05). The receiver operating characteristic curve, the area under the curve (ROC-AUC) (95%CI) values of serum HE-4 was 0.85 (0.74-0.95). The sensitivity and specificity of HE-4 in diagnosing malignant ovarian tumors was 84.84% and 75.00%, respectively at ideal cutoff point that provided the best and highest accuracy in our own study and its level was related to clinical staging.","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49624713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Predictive value of Serum IL-6 level and CRP titer in Determining the need for Antifungal Therapy in Pediatric Patients with Febrile Neutropenia","authors":"S. Ansari, T. Rostami, A. Kiumarsi","doi":"10.18689/MJCSR-1000107","DOIUrl":"https://doi.org/10.18689/MJCSR-1000107","url":null,"abstract":"","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43866756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Flash from the Back; Molecular and Epidemiological aspects of Breast Cancer in Last 15 Years","authors":"S. Zia, Z. Rahman, S. Baig, A. Mushtaq","doi":"10.18689/MJCSR-1000106","DOIUrl":"https://doi.org/10.18689/MJCSR-1000106","url":null,"abstract":"","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42928709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to Epigenetic treatment in Gastric Cancer Cells: a Mini Review","authors":"S. Taheri","doi":"10.18689/mjcsr-1000105","DOIUrl":"https://doi.org/10.18689/mjcsr-1000105","url":null,"abstract":"","PeriodicalId":92819,"journal":{"name":"Madridge journal of cancer study & research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43123829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：